Introduction
Background
In 1872, Kaposi was the first to report an idiopathic, multiple-pigmented sarcoma of the skin that predominantly affected elderly men of Mediterranean or Ashkenazi ancestry. This classic type has an indolent course and commonly presents on the lower extremities.
Since the original description, 3 additional forms have been described. Endemic Kaposi sarcoma is prevalent in central Africa, primarily affecting young men with aggressive skin and visceral lesions. Transplant-related Kaposi sarcoma has been reported in patients with renal transplants on immunosuppressive therapy. Epidemic Kaposi sarcoma, better known as AIDS-related Kaposi sarcoma, commonly affects homosexual males with AIDS. Prior to the AIDS epidemic of 1981, fewer than 25 reported cases of ophthalmic Kaposi sarcoma existed in the literature.
Pathophysiology
Whether the 4 variants of Kaposi sarcoma represent the same disease process or different processes that manifest the same end-stage lesion is unclear. Although the etiology has not been elucidated, the human herpesvirus 8 (HHV-8) has been implicated. In 1994, Chang et al identified this virus in more than 90% of patients with AIDS-related Kaposi sarcoma.
Frequency
United States
Prior to 1981, fewer than 25 reported cases of ophthalmic Kaposi sarcoma existed in the literature. Currently, the overwhelming majority of ophthalmic Kaposi sarcoma is AIDS related. In 1986, the Centers for Disease Control and Prevention (CDC) reported that Kaposi sarcoma occurs in approximately 24% of patients with AIDS and 35% of all homosexual men with AIDS. The CDC reported that during the period from 1992-1997, Kaposi sarcoma occurred in 23.8% of males with AIDS and 27.4% of all homosexual men with AIDS. During the same time period, only 2.3% of women with AIDS developed Kaposi sarcoma.
Ophthalmic involvement occurs in 20-24% of patients with AIDS-related Kaposi sarcoma. Ophthalmic presentation was the initial manifestation of AIDS-related Kaposi sarcoma in 4-12% of patients. Eye lesions are neither an early nor a late manifestation of Kaposi sarcoma. A review of the literature reports that most eye lesions involve the conjunctivae or eyelids; 10-75% of patients have conjunctival lesions, and 25-80% of patients have eyelid lesions.
In recent years, the incidence of Kaposi sarcoma among HIV patients has declined significantly, from 60.6% in 1992 to 19.7% in 1997. The exact cause for this decline is unclear, but the introduction of protease inhibitors, combination HIV therapy, and safer sexual practices may have played significant roles.
Mortality/Morbidity
- Systemic Kaposi sarcoma
- Tumors have been linked to significant mortality and morbidity. Kaposi sarcoma can disseminate to visceral organs (ie, lungs, liver, adrenal glands, kidneys, bone marrow, gastrointestinal tract).
- Bowel obstruction, lower extremity edema, shortness of breath, hemorrhage, and pain have been reported.
- Visceral and lung involvement usually portends a poor prognosis.
- Ophthalmic Kaposi sarcoma
- Generally, ophthalmic Kaposi sarcoma is indolent.
- Ocular tumor growth can result in severe damage to the ocular adnexa and the ocular surface.
- Involvement of the eyelids can cause significant disfigurement and lid dysfunction. Trichiasis can develop from mechanical ectropion or entropion. Lagophthalmos and trichiasis can result in profound irritation and dryness, infections, and corneal scarring. Large lid tumors can induce irregular corneal astigmatism. Conjunctival involvement may result in recurrent subconjunctival hemorrhages.
- Ultimately, vision could be lost from lid dysfunction, corneal surface changes, or visual obstruction.
Race
- Classic Kaposi sarcoma usually involves elderly men with Mediterranean or Ashkenazi ancestry.
- Endemic Kaposi sarcoma usually involves young black males from central Africa.
- Transplant- or AIDS-related Kaposi sarcoma has no racial preference.
Sex
- Classic Kaposi sarcoma usually involves elderly men.
- Endemic Kaposi sarcoma usually involves young males.
- AIDS-related Kaposi sarcoma predominantly involves homosexual males.
Age
- Classic Kaposi sarcoma affects the older population.
- Endemic Kaposi sarcoma affects children with a male-to-female ratio of 1:1; after puberty, males predominantly are affected.
- AIDS-related Kaposi sarcoma usually affects males aged 20-49 years.
Clinical
History
- Identify risk factors for Kaposi sarcoma. The clinician should ask about the following:
- Demographics
- Immune status
- Previous skin lesions
- Previous treatment for Kaposi sarcoma
- History of opportunistic infections
- Current medication use
- Symptoms of Kaposi sarcoma include the following:
- Pain
- Photophobia
- Recurrent red or bloody eyes
- Irritation and foreign body sensation
- Epiphora
- Dry eyes
- Mucopurulent discharge
- Heavy or swollen eyelids
- Cosmetic disfigurement of the eyelids
- Eyelashes rubbing against the eyes
- Inability to close the eyes
- Visual obstruction
- Blurred vision
Physical
- Full ocular examination should include the following:
- Inspect and evert the eyelids and lashes.
- Perform slit lamp biomicroscopy.
- Examine palpebral and bulbar conjunctivae and fornices in detail.
- Palpate the lacrimal gland, and examine for masses.
- Examine both eyes for proptosis in the rare likelihood of orbital involvement. Fortunately, intraocular Kaposi sarcoma has never been reported.
- The lesions are purplish red to bright red and highly vascular with surrounding telangiectatic vessels. They may be macular, plaquelike, or nodular.
- Dugel et al described 3 clinical stages that may help direct therapy.
- Stage I and II tumors are patchy and flat. These lesions have a thickness of less than 3 mm in vertical height and are younger than 4 months.
- Stage III tumors are nodular and elevated with a vertical height of greater than 3 mm. They tend to be older than 4 months.
- Ophthalmic Kaposi sarcoma lesions are found on the eyelids, conjunctiva, caruncle, and lacrimal sac. They rarely are found inside the orbit.
- Of ophthalmic Kaposi sarcoma cases, 6-16% are eyelid lesions, and the superior and inferior eyelids tend to be involved equally.
- Of ophthalmic Kaposi sarcoma cases, 7-18% are conjunctival lesions. Many conjunctival lesions tend to involve the inferior conjunctiva and fornix.
- Lesions tend to be indolent, but, as the tumor grows, it can alter ocular adnexal structures and the ocular surface. The mass effect of the tumor on the eyelids can cause mechanical ectropion or entropion with trichiasis and lagophthalmos and irregular astigmatism.
- Ectropion or entropion can result in poor lid apposition, trichiasis, and lagophthalmos. Consequently, the patient may experience epiphora, poor tear clearance and drainage, recurrent corneal abrasions, pain and discomfort, foreign body sensation, dry eyes, and photophobia.
- Long-standing trichiasis and exposure can result in corneal infection, scarring, and opacification.
- Rarely, tumor bulk may block the visual axis by ptosis or direct obstruction. Tumor bulk may even prevent the complete closure of the eyelid.
- Conjunctival involvement may present with subconjunctival hemorrhage, injection, and chemosis.
Causes
- HHV-8 has been implicated.
- Homosexual males with HIV are at an increased risk. This risk is increased markedly with the number of partners.
- Patients who have had organ transplants and use immunosuppressive agents and steroids are at an increased risk.
- Elderly males of Mediterranean or Ashkenazi ancestry are at an increased risk.
More on Kaposi Sarcoma |
 Overview: Kaposi Sarcoma |
| Differential Diagnoses & Workup: Kaposi Sarcoma |
| Treatment & Medication: Kaposi Sarcoma |
| Follow-up: Kaposi Sarcoma |
| Multimedia: Kaposi Sarcoma |
| References |
| Next Page » |
References
Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi''s sarcoma. J Clin Oncol. Aug 1995;13(8):1966-74. [Medline].
Brasnu E. Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol. 2005;140:746-748. [Medline].
Center for Disease Control. Surveillance for AIDS-Defining Opportunistic Illnesses. Morbidity and Mortality Weekly Report. Atlanta, Ga: Center for Disease Control;. 48:1-24.
Center for Disease Control. The Complete Reference for Generic and Brand Drugs. 9th ed. Mosby's GenRx; 1999.
Centers for Disease Control. Update: Acquired Immunodeficiency Syndrome - United States. Morbidity and Mortality Weekly Report. Atlanta, Ga: Center for Disease Control;. 35:17-21.
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi''s sarcoma. Science. Dec 16 1994;266(5192):1865-9. [Medline].
Dugel PU, Gill PS, Frangieh GT, Rao NA. Ocular adnexal Kaposi''s sarcoma in acquired immunodeficiency syndrome. Am J Ophthalmol. Nov 15 1990;110(5):500-3. [Medline].
Dugel PU, Gill PS, Frangieh GT, Rao NA. Treatment of ocular adnexal Kaposi''s sarcoma in acquired immune deficiency syndrome. Ophthalmology. Jul 1992;99(7):1127-32. [Medline].
Gigase PL, de Muynck A, de Feyter M. Kaposi''s sarcoma in Zaire. IARC Sci Publ. 1984;(63):549-57. [Medline].
Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi''s sarcoma. J Clin Oncol. Aug 1996;14(8):2353-64. [Medline].
Hermans P. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi''s sarcoma: 15-year lessons from AIDS. Biomed Pharmacother. 1998;52(10):440-6. [Medline].
Hermans P, Clumeck N, Picard O, et al. AIDS-related Kaposi''s sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. J Hum Virol. Jan-Feb 1998;1(2):82-9. [Medline].
Holland GN, Pepose JS, Pettit TH, et al. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. Aug 1983;90(8):859-73. [Medline].
Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. Apr 1982;93(4):393-402. [Medline].
Hummer J, Gass JD, Huang AJ. Conjunctival Kaposi''s sarcoma treated with interferon alpha-2a [letter]. Am J Ophthalmol. Oct 15 1993;116(4):502-3. [Medline].
Kaposi M. Idiopathisches multiple Pigment-sarkom der Haut. Arch Dermatol. Syphilol;1872:4. [Medline].
Mansour AM. Adnexal findings in AIDS. Ophthal Plast Reconstr Surg. Dec 1993;9(4):273-9. [Medline].
Meyers D. Eye signs that alert the clinician to a diagnosis of AIDS. SADJ. 2005;60:386-387. [Medline].
Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS- related Kaposi''s sarcoma after failure of standard chemotherapy. J Clin Oncol. Feb 1997;15(2):653-9. [Medline].
Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. Sep 1984;91(9):1092-9. [Medline].
Reitz MS Jr, Nerurkar LS, Gallo RC. Perspective on Kaposi''s sarcoma: facts, concepts, and conjectures. J Natl Cancer Inst. Sep 1 1999;91(17):1453-8. [Medline].
Samaniego F, Bryant JL, Liu N, et al. Induction of programmed cell death in Kaposi''s sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst. Jan 20 1999;91(2):135-43. [Medline].
Schuman JS, Orellana J, Friedman AH, Teich SA. Acquired immunodeficiency syndrome (AIDS). Surv Ophthalmol. May-Jun 1987;DA - 19870828(6):384-410. [Medline].
Shuler JD, Holland GN, Miles SA, et al. Kaposi sarcoma of the conjunctiva and eyelids associated with the acquired immunodeficiency syndrome. Arch Ophthalmol. Jun 1989;107(6):858-62. [Medline].
Simonart T, Noel JC, Andrei G, et al. Iron as a potential cofactor in the pathogenesis of Kaposi''s sarcoma?. Int J Cancer. Dec 9 1998;78(6):720-6. [Medline].
Stein M, Spencer D, Kuten A, Bezwoda W. AIDS-related Kaposi''s sarcoma: a review. Isr J Med Sci. Apr 1994;30(4):298-305. [Medline].
Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi''s sarcoma. J Clin Oncol. Mar 1998;16(3):1112-21. [Medline].
Yarchoan R. Therapy for Kaposi''s sarcoma: recent advances and experimental approaches. J Acquir Immune Defic Syndr. Aug 1 1999;21 Suppl 1:S66-73. [Medline].
Further Reading
Keywords
Kaposi's sarcoma, KS, idiopathic multiple pigmented sarcoma, endemic Kaposi sarcoma, transplant-related Kaposi sarcoma, epidemic Kaposi sarcoma, AIDS-related Kaposi sarcoma, ocular complications of AIDS, ophthalmic Kaposi sarcoma, ocular tumors, conjunctival tumors, conjunctival lesions, eyelid lesions, vascular tumors
